This application represents the renewal of the Specialized Program of Research Excellence in Kidney Cancer originating from the Kidney Cancer Program of the Dana-Farber Harvard Cancer Center (DF/HCC) and the Beth Israel Deaconess Medical Center. The DF/HCC Kidney Cancer SPORE includes investigators from all the Harvard affiliated hospitals - the Beth Israel Deaconess Medical Center, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Brigham and Women's Hospital, and the Children's Hospital Medical Center, as well as the Harvard School of Public Health. Five major projects are supported through this application including: 1) Clinical Correlations of WTX Inactivation in Wilms Tumor;2) Validation of RCC biomarkers for early disease detection and response to targeted therapy;3) Acquired Resistance to VEGF Receptor Blockade: Underlying Mechanism and Therapeutic Options;4), Targeting the PI3-Kinase/Akt Pathway in RCC: Mechanism of Action and Opportunities for Rational Combination Therapy;and 5) Adoptive Immunotherapy for Renal Carcinoma Using Dendritic Cell/tumor Fusions. These projects are integrated by three cores. These are: 1) Administration, Evaluation and Planning;2) Biostatistics;and 3) Tissue Acquisition, Pathology and Clinical Data, This SPORE application outlines a Development Research Program which includes a plan for selection and review of new projects and examples of 4 recently funded and 3 projects that could be considered for future support. We also include a Career Development Program which outlines a mechanism for the identification, support, and review of talented young investigators in renal cancer. The overall goal of the DF/HCC Kidney Cancer SPORE is the translation of biological and technological advances into clinically meaningful advances for patients with kidney cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA101942-10
Application #
8517013
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Program Officer
Hruszkewycz, Andrew M
Project Start
2003-09-18
Project End
2014-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
10
Fiscal Year
2013
Total Cost
$2,150,502
Indirect Cost
$484,525
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
McDermott, David F; Cheng, Su-Chun; Signoretti, Sabina et al. (2015) The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 21:561-8
Zerbini, Luiz Fernando; Bhasin, Manoj K; de Vasconcellos, Jaira F et al. (2014) Computational repositioning and preclinical validation of pentamidine for renal cell cancer. Mol Cancer Ther 13:1929-41
Akhavanfard, Sara; Vargas, Sara O; Han, Moonjoo et al. (2014) Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer 53:67-77
Bhatt, Rupal S; Atkins, Michael B (2014) Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors? Clin Cancer Res 20:2838-45
Choueiri, T K; Fay, A P; Gray, K P et al. (2014) PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 25:2178-84
Panka, David J; Buchbinder, Elizabeth; Giobbie-Hurder, Anita et al. (2014) Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther 13:3210-8
Gubin, Matthew M; Zhang, Xiuli; Schuster, Heiko et al. (2014) Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:577-81
Wang, Xiaoen; Bullock, Andrea J; Zhang, Liang et al. (2014) The role of angiopoietins as potential therapeutic targets in renal cell carcinoma. Transl Oncol 7:188-95
Davis, Caleb F; Ricketts, Christopher J; Wang, Min et al. (2014) The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26:319-30
Choueiri, Toni K; Je, Youjin; Cho, Eunyoung (2014) Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies. Int J Cancer 134:384-96

Showing the most recent 10 out of 63 publications